[{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"7204e2a6-dc66-4d87-87cb-75b6b508cd0a","acronym":"KisMET-01","url":"https://clinicaltrials.gov/study/NCT05652868","created_at":"2022-12-15T14:58:22.414Z","updated_at":"2025-02-25T15:20:09.822Z","phase":"Phase 1","brief_title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05652868 - KisMET-01","lead_sponsor":"Mythic Therapeutics","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYTX-011"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/23/2023","start_date":" 03/23/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-12"},{"id":"4811680a-497e-488d-8abd-34a9b22c5b1c","acronym":"TeliMET NSCLC-01","url":"https://clinicaltrials.gov/study/NCT04928846","created_at":"2021-06-16T18:52:53.966Z","updated_at":"2025-02-25T15:35:07.629Z","phase":"Phase 3","brief_title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04928846 - TeliMET NSCLC-01","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Recruiting","enrollment":" Enrollment 698","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-10"},{"id":"6206800b-ada7-4d44-b7fb-032aa56563fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084481","created_at":"2023-10-16T15:12:52.682Z","updated_at":"2024-07-02T16:34:26.033Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","source_id_and_acronym":"NCT06084481","lead_sponsor":"AbbVie","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 11/09/2023","start_date":" 11/09/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-14"},{"id":"701c790f-d71e-4882-8490-72c4deac7a2f","acronym":"BYON3521.001","url":"https://clinicaltrials.gov/study/NCT05323045","created_at":"2022-04-12T14:52:58.036Z","updated_at":"2024-07-02T16:34:37.322Z","phase":"Phase 1","brief_title":"A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521","source_id_and_acronym":"NCT05323045 - BYON3521.001","lead_sponsor":"Byondis B.V.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BYON3521"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"0709de84-6a21-4b70-87e0-b0abfb01cd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05513703","created_at":"2022-08-24T21:07:39.445Z","updated_at":"2024-07-02T16:35:09.671Z","phase":"Phase 2","brief_title":"A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05513703","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/18/2025","primary_completion_date":" 03/18/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-04-15"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"cc3db3b8-b381-4e3e-8f3a-6478dfee9150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617314","created_at":"2021-01-19T20:33:47.665Z","updated_at":"2024-07-02T16:35:18.619Z","phase":"Phase 1","brief_title":"A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04617314","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-20"},{"id":"30039935-dcb8-4bf7-a489-908bf7235f71","acronym":"LUMINOSITY","url":"https://clinicaltrials.gov/study/NCT03539536","created_at":"2021-01-18T17:26:22.732Z","updated_at":"2024-07-02T16:35:22.832Z","phase":"Phase 2","brief_title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03539536 - LUMINOSITY","lead_sponsor":"AbbVie","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • MET overexpression • MET expression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-01-19"},{"id":"4b9588e8-34ef-4f39-9824-5762f04f1e2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628857","created_at":"2022-11-29T15:57:45.073Z","updated_at":"2024-07-02T16:35:27.481Z","phase":"Phase 2","brief_title":"A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor","source_id_and_acronym":"NCT05628857","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2025","study_completion_date":" 10/15/2025","last_update_posted":"2023-11-30"},{"id":"4517ce65-ebe5-48ef-b3a0-5e1b03bf3e96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093503","created_at":"2023-10-23T20:13:56.005Z","updated_at":"2024-07-02T16:35:32.453Z","phase":"Phase 3","brief_title":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","source_id_and_acronym":"NCT06093503","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 04/11/2028","primary_completion_date":" 04/11/2028","study_txt":" Completion: 04/11/2028","study_completion_date":" 04/11/2028","last_update_posted":"2023-10-20"},{"id":"8a37d0f9-8abd-490b-aee8-74694dd7e0ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03859752","created_at":"2021-01-18T19:02:32.942Z","updated_at":"2024-07-02T16:35:36.034Z","phase":"Phase 1","brief_title":"TR1801-ADC in Patients With Tumors That Express c-Met","source_id_and_acronym":"NCT03859752","lead_sponsor":"Open Innovation Partners, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TR1801-ADC"],"overall_status":"Suspended","enrollment":" Enrollment 15","initiation":"Initiation: 08/14/2019","start_date":" 08/14/2019","primary_txt":" Primary completion: 07/04/2023","primary_completion_date":" 07/04/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-09-22"},{"id":"88937094-cd92-4d3c-b628-9e0e2ffc12f1","acronym":"M14-237","url":"https://clinicaltrials.gov/study/NCT02099058","created_at":"2021-01-17T17:35:29.259Z","updated_at":"2024-07-02T16:35:42.807Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02099058 - M14-237","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tagrisso (osimertinib) • erlotinib • Emrelis (telisotuzumab vedotin-tllv) • telisotuzumab (h224G11)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 04/24/2024","primary_completion_date":" 04/24/2024","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2023-07-17"},{"id":"895f148c-c60c-4d1f-8591-4efa7828dbdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856541","created_at":"2021-01-18T19:01:52.729Z","updated_at":"2024-07-02T16:36:01.650Z","phase":"Phase 1","brief_title":"A Study of SHR-A1403 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT03856541","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SHR-A1403"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/13/2019","start_date":" 02/13/2019","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 05/07/2020","study_completion_date":" 05/07/2020","last_update_posted":"2022-10-28"},{"id":"d13c635a-1aa3-4a77-af1d-2a98cdcc79c8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT03574753","created_at":"2021-01-18T17:35:20.794Z","updated_at":"2024-07-02T16:36:22.818Z","phase":"Phase 2","brief_title":"Lung-MAP S1400K: c-MET Positive","source_id_and_acronym":"NCT03574753 - LUNG-MAP SUB-STUDY","lead_sponsor":"Southwest Oncology Group","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emrelis (telisotuzumab vedotin-tllv)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 12/21/2019","primary_completion_date":" 12/21/2019","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2021-10-18"}]